Market revenue in 2023 | USD 78.6 million |
Market revenue in 2030 | USD 122.2 million |
Growth rate | 6.5% (CAGR from 2023 to 2030) |
Largest segment | Outpatient facilities |
Fastest growing segment | Home Care |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Hospitals, Outpatient Facilities, Home Care, Research & Manufacturing |
Key market players worldwide | Thermo Fisher Scientific Inc, Qiagen NV, Illumina Inc, Roche Holding AG ADR, BD, Agilent Technologies Inc, Myriad Genetics Inc, Koninklijke Philips NV, Abbott Laboratories, Hitachi Ltd, Danaher Corp, Prestige Medical |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to pancreatic cancer diagnostic market will help companies and investors design strategic landscapes.
Outpatient facilities was the largest segment with a revenue share of 62.72% in 2023. Horizon Databook has segmented the Australia pancreatic cancer diagnostic market based on hospitals, outpatient facilities, home care, research & manufacturing covering the revenue growth of each sub-segment from 2018 to 2030.
The pancreatic cancer diagnostics market in Australia is expected to grow significantly due to research collaborations and favorable government initiatives. In May 2022, the Australian Cancer Research Foundation (ACRF) launched the Child Cancer Liquid Biopsy Program for children with cancer.
Under this program, simple blood tests provide information about changes in a child with cancer and evaluate the treatment. Moreover, the Walter and Eliza Hall Institute of Medical Research (WEHI) is engaged in discovering new protein biomarkers for the discovery of pancreatic cancer.
In addition, in May 2024, a philanthropist and the President of WEHI donated USD 8 million for the establishment of a new, dedicated pancreatic cancer research center at WEHI. Such initiatives and funding are anticipated to fuel market growth over the forecast period.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia pancreatic cancer diagnostic market , including forecasts for subscribers. This country databook contains high-level insights into Australia pancreatic cancer diagnostic market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account